Table of Contents
chapter one: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Trends Affecting the Market
- Market Outlook
Chapter Two: Introduction and Overview
- Biogenerics Overview
- Biopharmaceutical Industry and the Approval Process
- Genetic Engineering
- Patent Approval
- Regulations for Biopharmaceuticals
- History of the Prescription Generic Pharmaceuticals Industry
- History of the Generic Approval Process
- Regulation of Prescription Generic Pharmaceuticals
- Biopharmaceuticals
- Areas of Treatment for Biopharmaceuticals
Chapter three: Market Analysis--Biologics with Currently Expired Patents
- Products
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
chapter Four: Market Analysis: Biologics with Currently Active Patents
- Products
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
Chapter Five: Issues and Trends
- Overview
- Regulatory and Legislative issues
- Europe
- United States
- Rest of World
- Scientific Issues
- Patent Issues
- Pricing Issues
- Barriers to Entry
- Innovator Strategies and Challenges
- Bulk Suppliers and Contract Manufacturing
- Bioequivalence Issues
- International Issues
- Low Cost Branded hGH
chapter Six: Market Summary
- Total Market Size and Forecast
- Competitive Analysis
chapter Seven: Company Profiles
- Analiza, Inc.
- Apotex, Inc.
- Barr Laboratories, Inc.
- BioGeneriX AG
- BioPartners GmbH
- Cangene Corporation
- Dr Reddys Laboratories Ltd.
- Dragon Pharmaceuticals, Inc.
- GeneMedix plc
- IVAX Corporation
- Microbix Biosystems, Inc.
- Rhein Biotech
- Sandoz
- Sicor, Inc.
- STADA Arzneimittel AG
- TEVA Pharmaceutical Industries, Ltd.
- Watson Pharmaceuticals, Inc.
appendix A: Biogeneric Company Directory
appendix B: Generic Industry Company Directory
List of Exhibits
Chapter one: Executive Summary
- Table 1-1: Total World Biogenerics Market Potential 2004-2010
- Figure 1-1: The World Market Potential for BioGeneric Drugs by Patent Segment 2004-2010
- Figure 1-2: The World Market Potential for BioGeneric Drugs 2010 Market Share by Current Patent Status
Chapter Two: Introduction and Overview
- Table 2-1: Scientific Differences of Pharmaceuticals and Biopharmaceuticals
Chapter three: Market Analysis: Biologics with Currently Expired Patents
- Table 3-1: Currently Marketed Biopharmaceuticals with Expired Patents (Product, Manufacturer, 2004 Sales, Patent Approval Date, Expiration Date, Known Generic Company Development)
- Table 3-2: Total World Biogenerics Market Potential for Products with Currently Expired Patents 2004-2010
- Table 3-3: Total U.S. Biogenerics Market Potential 2004-2010 for Products with Expired Patents
- Table 3-4: Total Non-U.S. Biogenerics Market Potential 2004-2010 for Products with Expired Patents
Chapter Four: Market Analysis: Biologics with Currently Active Patents
- Table 4-1: Currently Marketed Biopharmaceuticals with Active Patents (Product, Manufacturer, 2004 Sales, Patent Approval Date, Expiration Date, Known Generic Company Development)
- Table 4-2: Total World Biogenerics Market Potential for Products with Currently Active Patents 2004-2010
- Table 4-3: Total U.S. Biogenerics Market Potential for Products with Currently Active Patents 2004-2010
- Table 4-4: Total Non-U.S. Biogenerics Market Potential for Products with Currently Active Patents 2004-2010
Chapter Five: Issues and Trends
- Table 5-1: Estimates of Treatment Cost Per Patient of Selected Biopharmaceuticals
Chapter Six: Market Summary
- Table 6-1: Total World Biogenerics Market Potential 2004-2010
- Table 6-2: The World Market Potential for BioGeneric Drugs by Patent Segment 2004-2008
- Figure 6-1: Trending in the World Market Potential for BioGeneric Drugs by Patent Segment by Revenues 2004-2010
- Figure 6-2: The World Market Potential for BioGeneric Drugs by Segment: Market Share 2010
View Cart
